| Identification | Back Directory | [Name]
Kuguacin J | [CAS]
1141453-65-7 | [Synonyms]
Kuguacin J
19-Norlanosta-5,23,25-triene-9-carboxaldehyde, 3,7-dihydroxy-, (3β,7β,9β,10α,23E)- | [Molecular Formula]
C30H46O3 | [MDL Number]
MFCD25371936 | [MOL File]
1141453-65-7.mol | [Molecular Weight]
454.68 |
| Hazard Information | Back Directory | [Description]
Kuguacin J exerts growth inhibition through G1 arrest and induction of apoptosis in androgen-dependent human prostate cancer, it is a promising candidate new antineoplastic and chemopreventive agent for androgen-dependent prostate cancer and carcinogenesis.
Kuguacin J modulates the function of P-glycoprotein (P-gp) by directly interacting at the drug-substrate-binding site, and it appears to be an effective inhibitor of P-gp activity in vitro and thus could be developed as an effective chemosensitizer to treat multidrug-resistant cancers. | [target]
p21 | CDK | Bcl-2/Bax | Caspase | PARP | Androgen Receptor | p53 | P-gp |
|
|